Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2023-11-21
Summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Conditions
- Lymphoma, B-Cell
- Large B-cell Lymphoma
- Follicular Lymphoma
Interventions
- BIOLOGICAL
-
Relmacabtagene Autoleucel
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Sponsors & Collaborators
-
Shanghai Ming Ju Biotechnology Co., Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-28
- Primary Completion
- 2038-12-31
- Completion
- 2038-12-31
Countries
- China
Study Locations
More Related Trials
-
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
NCT05834751 ·Status: UNKNOWN ·Phase: NA
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
NCT00366418 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
NCT04693676 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
NCT03761056 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
NCT06026995 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826 ·Status: RECRUITING
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 ·Status: COMPLETED
-
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
NCT03299738 ·Status: UNKNOWN ·Phase: PHASE1
-
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
NCT00499018 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT03206970 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
NCT00285389 ·Status: COMPLETED ·Phase: PHASE2
-
ChiCGB vs BEAM in High-risk or R/R Lymphomas
NCT05466318 ·Status: RECRUITING ·Phase: PHASE3
-
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
NCT02805218 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
NCT03023878 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00049413 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
NCT01144403 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
NCT00532129 ·Status: COMPLETED ·Phase: PHASE2